Avidity Partners Management’s Keros Therapeutics KROS Stock Holding History

Avidity Partners Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-210,000	Closed	-$3.32M	–	78
2024 Q4	$3.32M	Sell	210,000 -83,200	-28%	-$4.32M	0.33%	55
2024 Q3	$17M	Sell	293,200 -50,000	-15%	-$2.47M	0.87%	47
2024 Q2	$15.7M	Buy	343,200 +133,500	+64%	+$7.17M	0.67%	53
2024 Q1	$13.9M	Buy	+209,700	New	+$12.4M	0.45%	62
2021 Q4	–	Sell	-145,100	Closed	-$5.74M	–	104
2021 Q3	$5.74M	Buy	+145,100	New	+$5.16M	0.13%	81
2021 Q1	–	Sell	-40,000	Closed	-$2.82M	–	109
2020 Q4	$2.82M	Buy	+40,000	New	+$2.52M	0.09%	88

Other funds holding KROS

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Avidity Partners Management's KROS Position: Q1 2025 in Review

Avidity Partners Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 210,000 shares — an estimated $3.32M sold.

Avidity Partners Management first reported a position in KROS in Q4 2020 and held it in 6 quarters. The position peaked at $17M in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

Avidity Partners Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
Avidity Partners Management sold 210,000 Keros Therapeutics shares in Q1 2025, an estimated $3.32M.
Avidity Partners Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 6 quarters.
Avidity Partners Management's Keros Therapeutics position peaked at $17M in Q3 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Avidity Partners Management's 13F filing for Q1 2025, filed 15 May 2025.